132 results on '"Zielinski C"'
Search Results
2. Time to treat the climate and nature crisis as one indivisible global health emergency
3. ESMO-Magnitude of Clinical Benefit Scale version 1.1
4. COP27 Climate Change Conference: urgent action needed for Africa and the world
5. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
6. Reply to the letter to the editor ‘Toxicity adjustment in the ESMO-MCBS: a Gestalt approach?’ by Del Paggio
7. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
8. Reply to the letter to the editor ‘The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice’ by Hartmann and the letter ‘Comment on ESMO Magnitude of Clinical Benefit Scale’ by Muhonen et al.
9. Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?
10. 229MO Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study
11. 415P Comparison of cetuximab every 2 weeks versus standard once-weekly administration for the first-line treatment of RAS wild-type metastatic colorectal cancer among patients with left- and right-sided primary tumor location
12. P-52 Overall survival with cetuximab every 2 weeks vs standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumor location
13. 472P Prevention of metastasis formation by combination therapy targeting Her2 and PD-L1 in Her2-expressing tumors based on observed efficacious vaccination against Her2-positive tumors
14. 1536P HERIZON: A phase II study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine plus standard of care chemotherapy in patients with HER2+ advanced stomach cancer - Dose-dependent anti-cancer antibodies correlating with improved clinical outcome
15. Delivering precision medicine in oncology today and in future—the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO)
16. Present and future breast cancer management—bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry
17. The landscape of medical oncology in Europe by 2020†
18. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24)
19. Reduced seroprevalence against vaccine preventable diseases (VPDs) in adult patients with cancer: necessity of routine vaccination as part of the therapeutic concept
20. PD-8 HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine plus SOC chemotherapy in patients with HER2+ advanced stomach cancer – correlation of the antibody responses and clinical outcome
21. FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study
22. Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer
23. Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents
24. Third CECOG consensus on the systemic treatment of non-small-cell lung cancer
25. 143P Quality of life (QoL) with palbociclib (PAL) plus endocrine therapy (ET) versus (vs) capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL study
26. Reply to Capecitabine dosing is not yet optimized for breast cancer
27. Trastuzumab treatment in patients with breast cancer and metastatic CNS disease
28. Reply to Third consensus on medical treatment of metastatic breast cancer
29. Third consensus on medical treatment of metastatic breast cancer
30. Absence of efficacy of thalidomide monotherapy in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma)
31. Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases
32. Second consensus on medical treatment of metastatic breast cancer
33. Bevacizumab is active in malignant effusion
34. ‘Blind’ antibiotic treatment targeting Chlamydia is not effective in patients with MALT lymphoma of the ocular adnexa
35. Beneficial effect of high-dose chemotherapy in multiple myeloma patients with unfavorable prognostic features
36. Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines
37. A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer
38. Reply to the letter to the editor ‘ESMO-MCBS v1.1: statistical and patient relevant shortcomings’ by Emprechtinger et al.
39. Chemotherapy for management of localised high-grade gastric B-cell lymphoma: how much is necessary?
40. Correcetions to “A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)”
41. Reply to the letter to the editor ‘Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies’
42. Reply to the letter to the editor ‘Addressing the quality of the ESMO-MCBS’ by Del Paggio
43. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
44. Reply to the letter to the editor ‘Utilisation of the ESMO-MCBS in practice of HTA’ by Wild et al.
45. Decreased body mass index (BMI) associates with impaired survival from diagnosis of brain metastases in lung cancer patients: analysis of 624 patients
46. Functional role of 4F2hc in pancreatic ductal adenocarcinoma
47. Exploratory analyses of candidate predictive and prognostic tissue biomarkers (BMs) in the open-label randomised phase III TANIA trial of bevacizumab (BEV) in HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
48. Temporal muscle thickness (TMT) is an independent prognostic parameter in patients with newly diagnosed brain metastases (BM) of breast cancer (BC)
49. P-177 Phase II trial of capecitabine + nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma
50. Activity of T-Dm1 in Her2-Positive Breast Cancer Brain Metastases
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.